Dear customers and shareholders:
The global spread of COVID-19 is affecting every one of us. The global response to meet the challenges of the pandemic - protecting the vulnerable, learning all we can about the virus, and caring for the infected - requires all of us to do our part to slow the spread. We want to provide you with information as to how Ventripoint is contributing through managing our business and continuing to develop our technology.
To reduce the risk of spreading the infection and to protect our staff, we have decided to have our staff work from home until further notice on the direction of the Government of Ontario and Federal Government of Canada. Our operations are still running and we remain available during regular business hours by phone (1-833-201-8735 within North America/1-800-7777-5500 outside of North America) or email: firstname.lastname@example.org to assist our customers.
Our sales initiatives are continuing, and the team has found alternative methods to engage with the medical community that do not involve in-person interactions. Our development team is exploring how our flagship product, VMS+3.0, will be able to provide an aid to help with diagnosis and care for patients that present with cardiovascular symptoms as a result of the COVID-19 infection.
Like many medical device companies, we want to do our part to help. We know that VMS+3.0 facilitates accurate measurements of heart function more quickly and at less expense than other modalities, such as MRI. This is especially true for the right heart, which is most affected by respiratory difficulties, such as those experienced in COVID-19.
These are challenging times for everyone and as this situation evolves, we commit to providing you with regular updates on our website.
Stay safe and healthy!
Dr. George Adams
Executive Chair & Acting CEO
Giving You Confidence in Your Volumetric Results
Ventripoint’s VMS+ 3.0 connects to any echocardiogram system providing cardiac measurements with accuracy equivalent to MRI for all 4 chambers of the heart
The system uses a proprietary Knowledge Based Reconstruction (KBR) technology creating 3D images of the heart from standard echo images
Reduce the number of adult and pediatric patients sent to an MRI for a volumetric assessment
FDA Cleared, Health Canada License and CE Marked
“The right heart is difficult to assess, and in patients with pulmonary disease, this challenge is even more difficult. Furthermore, in those patients with pulmonary hypertension, the Ventripoint technology gives us an ability to repeatedly evaluate the right-ventricular dimensions with a rapid, inexpensive, non-invasive procedure to determine therapeutic efficacy,” commented Dr. Marloes Huitema, MD Cardiology at St. Antonius Hospital